A systematic review of the effects of increasing arachidonic acid intake on PUFA status, metabolism and health-related outcomes in humans.
Level 1 - systematic review of randomized trials
Systematic review of 14 randomized controlled trials
PubMed 31130146 · doi:10.1017/S0007114519000692
What was done
Systematic review of randomized controlled trials (RCTs) evaluating the effects of increased arachidonic acid (ARA) intake on fatty acid status, metabolism, and health outcomes in humans. The authors identified 22 articles representing 14 RCTs, mostly in adults, using ARA doses from 80 to 2000 mg/day over durations of 1 to 12 weeks.
What was found
ARA supplementation at doses as low as 80 mg/day increased ARA content in various blood fractions. Increasing intake from typical baseline levels (100–200 mg/day) up to 1000–2000 mg/day produced few marked health benefits, though potential effects on cognitive and muscle function in older adults were noted. Supplemental intake up to 1000–1500 mg/day showed no adverse effects on blood lipids, platelet aggregation, blood clotting, immune function, inflammation, or urinary excretion of ARA metabolites. No specific quantitative effect sizes or pooled numerical results were reported in the abstract.
Why it matters
This review indicates that dietary ARA can safely raise tissue fatty acid levels without triggering adverse inflammatory or thrombotic events in the short term, but current evidence does not support recommending supplementation for distinct clinical benefits.
Limits
Total participant count was not reported in the abstract. Study durations were short (1–12 weeks), and the overall evidence base remains small (14 trials) with insufficient data to establish firm conclusions or clinical guidelines.
Cited by
- contradicts Omega-3 polyunsaturated fatty acids from fish oils lower triglycerides, whereas omega-6 polyunsaturated fatty acids are pro-inflammatory.